Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans - PubMed (original) (raw)

Clinical Trial

doi: 10.1096/fj.03-1086fje. Epub 2004 Mar 19.

Affiliations

• PMID: 15033935
• DOI: 10.1096/fj.03-1086fje

Clinical Trial

Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans

Cedric Moro et al. FASEB J. 2004 May.

Abstract

In humans, lipid mobilization is considered to depend mainly on sympathetic nervous system activation and catecholamine action. A contribution of ANP was hypothesized because we have previously shown that atrial natriuretic peptide (ANP) is a lipolytic agent on isolated human fat cells. Control of lipid-mobilizing mechanisms was investigated using in situ microdialysis in subcutaneous adipose tissue (SCAT) in healthy young men during two successive exercise bouts performed at 35% and 60% peak oxygen consumption (VO2max) after placebo or acute oral tertatolol (nonselective beta-antagonist) treatment. In placebo-treated subjects, infusion of propranolol in the probe (100 micromol/l) only partially reduced (40%) the increment in extracellular glycerol concentration (EGC) promoted by exercise. Moreover, oral beta-adrenergic receptor blockade did not prevent exercise-induced lipid mobilization in SCAT while exerting fat cell beta-adrenergic receptor blockade. Exercise-induced increase in plasma ANP was potently amplified by oral tertatolol. A positive correlation was found between EGC and plasma ANP levels but also between extracellular cGMP (i.e., index of ANP-mediated lipolysis) and EGC. Thus, we demonstrate that exercise-induced lipid mobilization resistant to local propranolol and lipid-mobilizing action observed under oral beta-blockade is related to the action of ANP. Oral beta-adrenergic receptor blockade, which potentiates exercise-induced ANP release by the heart, may contribute to lipid mobilization in SCAT. The potential relevance of an ANP-related lipid-mobilizing pathway is discussed.

PubMed Disclaimer

Similar articles

• Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise.
  Moro C, Polak J, Hejnova J, Klimcakova E, Crampes F, Stich V, Lafontan M, Berlan M. Moro C, et al. Am J Physiol Endocrinol Metab. 2006 May;290(5):E864-9. doi: 10.1152/ajpendo.00348.2005. Epub 2005 Nov 15. Am J Physiol Endocrinol Metab. 2006. PMID: 16291573 Clinical Trial.
• Exercise-induced lipid mobilization in subcutaneous adipose tissue is mainly related to natriuretic peptides in overweight men.
  Moro C, Pillard F, de Glisezinski I, Klimcakova E, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Moro C, et al. Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E505-13. doi: 10.1152/ajpendo.90227.2008. Epub 2008 Jun 17. Am J Physiol Endocrinol Metab. 2008. PMID: 18559985 Clinical Trial.
• [Natriuretic peptides: a new lipolytic pathway in human fat cells].
  Sengenes C, Moro C, Galitzky J, Berlan M, Lafontan M. Sengenes C, et al. Med Sci (Paris). 2005 Dec;21 Spec No:29-33. Med Sci (Paris). 2005. PMID: 16598902 Review. French.
• [Natriuretic peptides: a new lipolytic pathway in human fat cells].
  Sengenes C, Moro C, Galitzky J, Berlan M, Lafontan M. Sengenes C, et al. Med Sci (Paris). 2005 Jan;21(1):61-5. doi: 10.1051/medsci/200521161. Med Sci (Paris). 2005. PMID: 15639022 Review. French.
• Activation of antilipolytic alpha(2)-adrenergic receptors by epinephrine during exercise in human adipose tissue.
  Stich V, de Glisezinski I, Crampes F, Suljkovicova H, Galitzky J, Riviere D, Hejnova J, Lafontan M, Berlan M. Stich V, et al. Am J Physiol. 1999 Oct;277(4):R1076-83. doi: 10.1152/ajpregu.1999.277.4.R1076. Am J Physiol. 1999. PMID: 10516247

Cited by

• GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
  Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. Kim M, et al. Nat Med. 2013 May;19(5):567-75. doi: 10.1038/nm.3128. Epub 2013 Mar 31. Nat Med. 2013. PMID: 23542788
• Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis.
  Moro C, Klimcakova E, Lafontan M, Berlan M, Galitzky J. Moro C, et al. Br J Pharmacol. 2007 Dec;152(7):1102-10. doi: 10.1038/sj.bjp.0707485. Epub 2007 Oct 1. Br J Pharmacol. 2007. PMID: 17906676 Free PMC article.
• Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.
  Dias S, Paredes S, Ribeiro L. Dias S, et al. Int J Endocrinol. 2018 Jan 17;2018:2637418. doi: 10.1155/2018/2637418. eCollection 2018. Int J Endocrinol. 2018. PMID: 29593789 Free PMC article. Review.
• Natriuretic Peptides and Cardiometabolic Health.
  Gupta DK, Wang TJ. Gupta DK, et al. Circ J. 2015;79(8):1647-55. doi: 10.1253/circj.CJ-15-0589. Epub 2015 Jun 23. Circ J. 2015. PMID: 26103984 Free PMC article. Review.
• Involvement of the atrial natriuretic peptide in cardiovascular pathophysiology and its relationship with exercise.
  de Almeida JC, Alves CL, de Abreu LC, Sato MA, Fonseca FL, de Mello Monteiro CB, Vanderlei LC, Macedo H Jr, Tavares CM, Herrero D, Rodrigues LM, Valenti VE. de Almeida JC, et al. Int Arch Med. 2012 Feb 7;5(1):4. doi: 10.1186/1755-7682-5-4. Int Arch Med. 2012. PMID: 22313592 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information